Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

Dr. DeAngelo, Chief, Division of Leukemia, Institute Physician, Professor of Medicine, Harvard Medical School, explains the significance of the updated survival data for gilteritinib in acute myeloid leukemia (AML)

Tags: ASCO Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 03 June 2019

Recent Videos

video

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma

Dr. Wang, MD, Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, speculates on therapies ...

video

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma

Dr. Wang, Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, offers his opinion on ...

video

Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction

Dr. Martens, Resident Physician, Internal Medicine, University of Washington, discusses the advantages of rasburicase compared to allopurinol in managing tumor ...

video

Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol

Dr. Martens, Resident Physician, Internal Medicine, University of Washington, describes those patient types more suited for treatment with rasburicase versus ...

video

Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019

Dr. Topp, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, shares the long-term results of the ZUMA-1 trial ...

video

Kylee Martens, MD, considers whether there are certain patient types more prone to TLS

Dr. Martens, Resident Physician, Internal Medicine, University of Washington, considers whether there are particular patient types more prone to tumor ...

video

Luciano J. Costa, MD, PhD, on whether minimal residual disease can be used to predict outcomes

Dr. Costa, Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama ...

video

Robert Rifkin, MD, FACP, tells us about the outcomes of the LYRA study presented at ASH 2019

Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, tells us about the outcomes of the LYRA ...

video

Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials

Dr. Costa, Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama ...

video

Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma

Dr. Diefenbach, Director, Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, explains how combination therapies are evolving to ...

Related Videos

video-image

Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019

video-image

James McCloskey, MD, considers how the role of molecular profiling in AML is changing

video-image

Catherine Diefenbach, MD, regarding the unmet needs in the management of follicular lymphoma

video-image

Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol

video-image

Andrew Cowan, MD, on the most promising clinical data in multiple myeloma presented at ASH 2019

video-image

Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma

video-image

Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction

video-image

Michael Jain, MD, shares the outcomes of the US CAR-T Cell Consortium study from ASH 2019

video-image

Joseph Alvarnas, MD, on the challenges facing cancer centers when delivering innovative therapies

video-image

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma

video-image

James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019

video-image

Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia

video-image

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma

video-image

Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy

video-image

Joseph Alvarnas, MD, on seeking creative solutions to provide proper access to innovative therapy

video-image

Joseph Alvarnas, MD, on how to responsibly integrate clinical innovations into treatment algorithms

video-image

Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma

video-image

Andrew Cowan, MD, elaborates on the role of isatuximab in the management of multiple myeloma

video-image

Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials

video-image

Catherine Diefenbach, MD, on the recent data investigating obinutuzumab in follicular lymphoma